The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | The importance of the multidisciplinary team in treating patients with myeloma and amyloidosis
Naresh Bumma, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, emphasizes the importance of involving a multidisciplinary team (MDT) in the treatment of patients with multiple myeloma and amyloidosis to achieve a more personalized treatment approach for these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Membership on an entity’s Board of Directors or advisory committees, Other: Ad Board; Sanofi, Genzyme: Other: Ad Board, Speakers Bureau; Amgen: Consultancy, Speakers Bureau
